[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630915":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":12,"centralContacts":22,"locations":28,"responsibleParty":52,"collaborators":12,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":56,"sex":62,"minAge":63,"maxAge":12,"enrollmentInfo":64,"targetDuration":12,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":73,"overallStatus":31,"whyStopped":12,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Fondazione del Piemonte per l'Oncologia","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Usual Perioperative Management","NO_INTERVENTION","Participants enrolled during the first study period (approximately 4 months; expected n=100) will undergo usual perioperative management for cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) as routinely practiced at each participating center.",null,{"label":14,"type":6,"description":15,"interventionNames":16},"ERAS Perioperative Management Protocol","Participants enrolled during the second study period (approximately 8 months; expected n=200) will undergo perioperative management according to a predefined Enhanced Recovery After Surgery (ERAS) protocol including preoperative counseling and prehabilitation, nutritional assessment and support, optimized fasting and carbohydrate loading, standardized antibiotic and antithrombotic prophylaxis, multimodal analgesia, goal-directed or restrictive fluid therapy, early oral intake, glycemic control, early mobilization, and discharge-readiness assessment.",[17],"Other: ERAS Perioperative Management Protocol",[19],{"type":6,"name":14,"description":20,"armGroupLabels":21,"otherNames":12},"A multimodal perioperative care pathway for patients undergoing cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC), implemented by a multidisciplinary Enhanced Recovery After Surgery (ERAS) team and including coordinated preoperative, intraoperative, and postoperative measures aimed at reducing surgical stress and improving recovery.",[14],[23],{"name":24,"role":25,"phone":26,"phoneExt":12,"email":27},"Manuela Robella, MD","CONTACT","+390119933445","manuela.robella@ircc.it",[29,43],{"facility":30,"status":31,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":12},"Fondazione del Piemonte per l'Oncologia- IRCCS Istituto di Candiolo","RECRUITING","Candiolo","Turin","10060","Italy","IT",{"type":38,"coordinates":39},"Point",[40,41],7.59812,44.95858,{"lat":41,"lon":40},{"facility":44,"status":45,"city":46,"state":12,"zip":12,"country":35,"countryCode":36,"cosmosGeoPoint":47,"geoPoint":51,"contacts":12},"Fondazione IRCCS Policlinico San Matteo","NOT_YET_RECRUITING","Pavia",{"type":38,"coordinates":48},[49,50],9.15917,45.19205,{"lat":50,"lon":49},{"type":53,"investigatorFullName":12,"investigatorTitle":12,"investigatorAffiliation":12,"oldNameTitle":12,"oldOrganization":12},"SPONSOR","100630915","enhanced-recovery-after-surgery-eras-in-patients-with-peritoneal-carcinomatosis-undergoing-cytoreductive-surgery-with-or-without-hyperthermic-intraperitoneal-chemotherapy-hipec-100630915",false,"NCT07493876","Enhanced Recovery After Surgery (ERAS) in Patients With Peritoneal Carcinomatosis Undergoing Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)","Prospective Multicenter Interventional Pre-Post Study of an Enhanced Recovery After Surgery (ERAS) Protocol in the Perioperative Management of Patients With Peritoneal Carcinomatosis Undergoing Cytoreductive Surgery With or Without HIPEC (EPICH)","EPICH","Inclusion Criteria:\n\n* Written informed consent signed before the procedure\n* Histological or cytological diagnosis of advanced solid tumor with documented peritoneal carcinomatosis originating from one of the following: peritoneal mesothelioma or other primary malignant peritoneal tumor, gynecologic tumor, gastric tumor, or intestinal tumor\n* Age \\>18 years\n* ECOG performance status ≤1\n* ASA score ≤3\n\nExclusion Criteria:\n\n* Missing written informed consent\n* ASA score ≥4\n* Palliative surgery or other unplanned surgery\n* Severe renal insufficiency, severe hepatic insufficiency, severe heart failure, recent myocardial infarction, or severe arrhythmia\n* Immunocompromised patients, patients receiving immunosuppressive therapy, or patients with immune system diseases","ALL","18 Years",{"count":65,"type":66},300,"ESTIMATED","INTERVENTIONAL",[69],"NA","This prospective multicenter interventional pre-post study aims to evaluate the effect of implementing an Enhanced Recovery After Surgery (ERAS) protocol in patients with peritoneal carcinomatosis undergoing cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC). Approximately 300 patients will be enrolled across 20 Italian centers. During an initial pre-intervention period, usual perioperative management will be described; during a subsequent intervention period, participating centers will apply a predefined ERAS protocol. The primary objective is to assess the effect of ERAS implementation on mean postoperative hospital length of stay.",[72],"Peritoneal Carcinomatosis",[74,75,76,77,78],"Cytoreductive Surgery","HIPEC","Enhanced Recovery After Surgery","ERAS","Peritoneal Surface Malignancies","2026-03-30",{"date":81,"type":82},"2026-04-03","ACTUAL",{"date":84,"type":82},"2025-01-23",{"date":86,"type":66},"2027-12-30",{"name":5,"class":6},2]